Leukemia, Myelomonocytic, Chronic
"Leukemia, Myelomonocytic, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
Descriptor ID |
D015477
|
MeSH Number(s) |
C04.557.337.539.522 C15.378.190.615.510
|
Concept/Terms |
Leukemia, Myelomonocytic, Chronic- Leukemia, Myelomonocytic, Chronic
- Myelomonocytic Leukemia, Chronic
- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemias
- Leukemia, Chronic Myelomonocytic
- Leukemias, Chronic Myelomonocytic
- Myelomonocytic Leukemias, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelomonocytic, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelomonocytic, Chronic".
This graph shows the total number of publications written about "Leukemia, Myelomonocytic, Chronic" by people in this website by year, and whether "Leukemia, Myelomonocytic, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myelomonocytic, Chronic" by people in Profiles.
-
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leuk Lymphoma. 2023 02; 64(2):473-477.